6505--Fluticasone/Salmeterol Inh Powder

Amendment / Modification

This amendment modifies Solicitation Number 36E79726R0009.

• Correction to Annual Estimates: The annual estimates for Line Item 1 have been corrected from 317,019 to 371,019 canisters.

• Extension of Offer Due Date: The deadline for receipt of offers has been extended to March 18, 2026, at 2:30 PM Central Time.

• Pages 2-3 of the amendment: Contain corrected Continuation of SF-1449 pages for offerors to insert their proposed pricing.

• Solicitation Section B, Scope of Contract: While not explicitly stated as changed, the correction to Line Item 1's estimate implies a modification to the quantities within the scope.

• Offerors must use the corrected pricing pages (Pages 2-3 of this amendment) to insert their proposed pricing.

• Offerors must complete and sign Block 15 of this amendment and return it with all other offer documents.

• The due date for offers is now March 18, 2026, at 2:30 PM Central Time.

• All other terms and conditions of the original solicitation remain unchanged.

Amendment / Modification

This amendment extends the proposal due date for Solicitation 36E79726R0009.

• The closing date for receipt of offers is extended.

• The original closing date of 3/9/2026, 2:30 PM CT has been extended to 3/16/2026, 2:30 PM CT.

• All other terms and conditions of the original solicitation remain unchanged.

Solicitation / RFP / RFQ

This solicitation seeks proposals for the supply of Fluticasone/Salmeterol inhalers (oral powder, 60 doses, 30-day supply) in three different strengths: 100mcg/50mcg, 250mcg/50mcg, and 500mcg/50mcg. The contract will be a Firm Fixed Price, Indefinite-Delivery Requirements contract, supporting the VA and DoD Pharmaceutical Prime Vendor (PPV) Programs nationwide.

• Three specific strengths of Fluticasone/Salmeterol inhalers.

• Products must meet FDA approval and cGMP standards.

• Packaging must comply with specific requirements, including bar coding.

• Offerors must provide a unique 11-digit National Drug Code (NDC) for each offered item.

• Drug Supply Chain Security Act (DSCSA) requirements must be met.

• The contract will have a base ordering period of one year, with four one-year option periods.

• The total contract duration, including options, cannot exceed five years.

• Payments will be made through Government Prime Vendors, not directly from the Government.

• Proposals must be submitted via email to Youlanda.Duggar@va.gov and Teresa.Hussain@va.gov by the Offer Due Date: 03-09-2026, 2:30pm CT.

• Offers must include pricing for the base year and all four option years for all three line items.

• Award will be made to the lowest price technically acceptable offer.

• Technical acceptability includes meeting product descriptions, unique NDC, FDA approval, and cGMP compliance.

• Pricing must not exceed two decimal places and must include a 0.5% Cost Recovery Fee.

• This acquisition is unrestricted.

• Other than small businesses are required to submit an approved subcontracting plan for contracts over $900,000.

• Offerors must have an FDA approved NDA, ANDA, or BLA on file for offered drugs.

• If not the manufacturer, a Letter of Commitment from the manufacturer is required.

• Attachments A and B list the VA and DoD Pharmaceutical Prime Vendor contractors.

• Attachment C provides estimated annual requirements by agency.

• Attachment D provides a template for Small Business Subcontracting Plans.

Solicitation / RFP / RFQ

This is a pre-solicitation notice for an unrestricted procurement of Fluticasone/Salmeterol Inhaler for the Department of Veterans Affairs (VA) and other federal agencies including the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The VA National Acquisition Center intends to issue a Request for Proposal (RFP) to award one contract for an uninterrupted source of supply.

• Procurement of Fluticasone/Salmeterol Inhaler, Oral Powder.

• Offerors must specify the exact name and strength of the drug offered.

• Offerors must provide a unique 11-digit NDC number specific to their company and the drug.

• The successful offeror's label with its unique NDC will be the only label permitted on the product.

• All inhalers must be individually boxed and contain a bar code.

• Bottles must be compatible with automated dispensing units; glass bottles are not acceptable.

• Offerors certify that all offered products have passed required stability testing for all proposed package sizes.

• Contract period: One year plus four pre-priced one-year option periods.

• Distribution: Through VA's and DOD's respective Pharmaceutical Prime Vendor Programs.

• Solicitation Number: 36E79726R0009

• Solicitation Issue Date: On or about February 23, 2026.

• Response Date/Time/Zone: March 9, 2026, 2:30 PM CENTRAL TIME, CHICAGO, USA.

• Submission Format: Electronically issued in commercial item format in accordance with FAR Part 12.

• All responsible sources may submit an offer.

• Unrestricted procurement.

• Estimated annual requirements are provided for three line items:

  • Line Item 1: FLUTICASONE 100MCG/SALMETEROL 50MCG INHL, ORAL POWDER 60 Doses (Est. Annual Usage: 317,019 Canisters)
  • Line Item 2: FLUTICASONE 250MCG/SALMETEROL 50MCG INHL, ORAL, POWDER 60 Doses (Est. Annual Usage: 1,479,360 Canisters)
  • Line Item 3: FLUTICASONE 500MCG/SALMETEROL 50MCG INHL, ORAL, POWDER 60 Doses (Est. Annual Usage: 504,192 Canisters)

• Items are identified in the Schedule of Supplies and Attachment C.

• No paper copies of the solicitation will be available. Interested offerors should check SAM.gov continuously for updates.

• Point of Contact: Youlanda Duggar, Youlanda.Duggar@va.gov, 708-786-4943.